Advances in adhesion-related pathogenesis in Mycoplasma pneumoniae infection
- PMID: 40771685
- PMCID: PMC12325244
- DOI: 10.3389/fmicb.2025.1613760
Advances in adhesion-related pathogenesis in Mycoplasma pneumoniae infection
Abstract
Mycoplasma pneumoniae is a leading cause of community-acquired pneumonia (CAP) and upper respiratory tract infections, particularly in children and immunocompromised individuals. The growing global prevalence of macrolide-resistant M. pneumoniae (MRMP) further emphasizes the urgent need to elucidate its pathogenic mechanisms. Among these, adhesion plays a central role, serving as a prerequisite for colonization and disease progression, and thus warrants detailed investigation. The terminal organelle of M. pneumoniae mediates both adhesion and gliding motility, facilitating colonization, tissue invasion, and potential systemic spread. In the lung, adhesion triggers cytotoxic effects through the release of hydrogen peroxide (H2O2) and CARDS toxin (CARDS TX), promotes excessive inflammatory responses, and enables immune evasion via antigenic variation. Extrapulmonary manifestations may also arise either from direct bacterial dissemination or autoimmune responses induced by molecular mimicry between bacterial and host antigens. In addition, recent advances suggest that therapies and vaccines directed at the adhesion mechanism of M. pneumoniae may offer promising strategies for combating MRMP infections. Although progress has been made, the adhesion-related pathogenesis of M. pneumoniae, as well as the prospects for therapies and vaccines targeting this mechanism, remains incompletely defined. This review synthesizes current insights into adhesion-mediated mechanisms and highlights emerging therapeutic strategies targeting adhesion, aiming to support more effective treatment and prevention of M. pneumoniae infection.
Keywords: M. pneumonia; adhesion; terminal organelle; treatment; vaccines.
Copyright © 2025 Sun, Ling, Li, Ma, Jie, Luo, Li, Yin, Wang, Meng and Gao.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures






Similar articles
-
Mycoplasma pneumoniae: Among the smallest bacterial pathogens with great clinical significance in children.Indian J Med Microbiol. 2023 Nov-Dec;46:100480. doi: 10.1016/j.ijmmb.2023.100480. Epub 2023 Sep 21. Indian J Med Microbiol. 2023. PMID: 37741157 Review.
-
Antibiotics for community-acquired lower respiratory tract infections secondary to Mycoplasma pneumoniae in children.Cochrane Database Syst Rev. 2012 Sep 12;(9):CD004875. doi: 10.1002/14651858.CD004875.pub4. Cochrane Database Syst Rev. 2012. Update in: Cochrane Database Syst Rev. 2015 Jan 08;1:CD004875. doi: 10.1002/14651858.CD004875.pub5. PMID: 22972079 Updated.
-
Antibiotics for community-acquired lower respiratory tract infections secondary to Mycoplasma pneumoniae in children.Cochrane Database Syst Rev. 2015 Jan 8;1(1):CD004875. doi: 10.1002/14651858.CD004875.pub5. Cochrane Database Syst Rev. 2015. PMID: 25566754 Free PMC article.
-
Antibiotics for community-acquired lower respiratory tract infections secondary to Mycoplasma pneumoniae in children.Cochrane Database Syst Rev. 2010 Jul 7;(7):CD004875. doi: 10.1002/14651858.CD004875.pub3. Cochrane Database Syst Rev. 2010. Update in: Cochrane Database Syst Rev. 2012 Sep 12;(9):CD004875. doi: 10.1002/14651858.CD004875.pub4. PMID: 20614439 Updated.
-
Systemic Inflammatory Response Syndrome.2025 Jun 20. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2025 Jun 20. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 31613449 Free Books & Documents.
References
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous